Journal Article

A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease

Jing Chen, Shuang-Shuang Zhang, Xiao-Hong Hu, Shashank R. Joshi, Wei Ye, Maria Paula Macedo, Ali Kirik, Ping-Ge Yuan, Laurens A. Van Kleef, Omar M. Ghanem, Yi-Min Zhang, Hong-Wen Zhou, Hasmik Levon Ghazinyan, Pal Novak Kaposi, Alessandro Federico, Xiao-Hua Duan, Xiang Hu, Xu-Jing Liang, Eduardo Garcia Pacheco, Giovanni Targher, Marat Fudim, Xiao-Guang Dou, Yeonjung Ha, Mohamed Hany, Bing Hu, Yi-Cong Xu, Qin-Fen Chen, Jin Li, Qiuwei Pan, George Lau, Pierluigi Marzuillo, Yan-Qing Xing, Dan Lucian Dumitrascu, Dan-Dan Zhao, Hui Liang, Yun-Zhi Chen, Gang Chen, Seung Up Kim, Raghu Ramanathan, Meri Trajkovska, Beniamino Pascotto, Xiaolong Qi, Maria Teresa Arias-Loste, Débora Acín-Gándara, Fatima Higuera-de-la-Tijera, Huai Zhang, Antonietta Gerarda Gravina, Xin Yin, Ming-Feng Xia, Ling-Juan Fang, Wei Liu, Giuliano Peixoto Campelo, Bing Wang, Qing-Long Jin, Cui-Cui Shi, Qiang Zhao, Jose Eduardo Garcia Flores, Jian-Sheng Zhu, Coskun Ozer Demirtas, Teruki Miyake, Nissar Hussain Hamdani, Lee-Ling Lim, Kengo Moriyama, Maria L. Martinez Chantar, Andrea Ruzzenente, Jordi Gracia-Sancho, Chun-Ming Li, Li Hong, Xiao-Dong Zhou, Wei-Jiang Y

2024

Overview

Background With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11. Methods Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members. Results A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p  = 0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%). Conclusions This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision.

• Publisher: Springer Science and Business Media LLC,Springer India,Springer Nature B.V
• Subject: Associations / Chi-square test / Classification / Clinical Medicine / Clinical Medicine (Med) / Coding / Colorectal Surgery / Comorbidity / Dahili Tıp Bilimleri / Diabetes mellitus / Fatty liver / Gastroenterology & Hepatology / Gastroenterology and Hepatology / Gastroenteroloji Ve Hepatoloji / Gastroenteroloji-(Hepatoloji) / Global Health / Global survey / Global survey; ICD-11; MAFLD / Global survey; MAFLD; ICD-11 / Health Sciences / Hepatology / Hepatoloji / Humans / ICD-11 / Internal Diseases / Internal Medicine Sciences / International Classification of Diseases / İç Hastalıkları / Klinik Tıp / Klinik Tıp (Med) / Liver / Liver diseases / MAFLD / Medical records / Medicine / Medicine & Public Health / Metabolism / Multiple choice / Nomenclature / Non-alcoholic Fatty Liver Disease - classification / Non-alcoholic Fatty Liver Disease - epidemiology / Original Article / Questionnaires / Revisions / Sağlık Bilimleri / SDG 3 - Good Health and Well-being / Surgery / Surveys / Surveys and Questionnaires / Tıp